Source: Annual Congress 2001 - Presentation and imaging of TB
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
L. V. Panova, E. S. Ovsyankina (Moscow, Russia). Reasons for hepatotoxic reactions to chemotherapeutic agents and possibilities of their prevention in adolescents with tuberculosis. Eur Respir J 2001; 16: Suppl. 31, 3115

Member's Comments

No comment yet.

Related content which might interest you: Experimental justification choise to prevent hepatotoxic reactions to anti-TB drugs based on gene-phenotypic characteristics Source: International Congress 2019 – Tuberculosis: diagnosis Year: 2019 Current approaches to the prevention of tuberculosis in patients receiving immunosuppressants Source: Virtual Congress 2021 – Epidemiological aspects of tuberculosis Year: 2021 Appreciation efficiency of standard and alternative antituberculosis preventive therapy in children from different tuberculosis infection sources Source: Eur Respir J 2006; 28: Suppl. 50, 28s Year: 2006 Rational use of tuberculosis drugs to prevent the development of drug resistance Source: Annual Congress 2012 - MDR- and XDR-TB: epidemiological and public health overview Year: 2012 Screening for tuberculosis in candidates for immunosuppressive therapy Source: Annual Congress 2009 - Clinical immunology of tuberculosis Year: 2009 Retrial of identical agents in patients with toxic hepatitis caused by first line antituberculosis drugs Source: Annual Congress 2010 - Adverse events of antituberculosis treatment and comorbidities Year: 2010 The experience of overcome of Mcb.tuberculosis resistance to antituberculosis drugs Source: Eur Respir J 2002; 20: Suppl. 38, 613s Year: 2002 Monitoring of antituberculous drugs adverse events during the treatment of multidrug-resistant pulmonary tuberculosis Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011 Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis Source: Eur Respir J , 49 (4)  1700317; DOI: 10.1183/13993003.00317-2017 Year: 2017 Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis Source: Eur Respir J , 49 (4)  1700173; DOI: 10.1183/13993003.00173-2017 Year: 2017 Targeting harmful use of alcohol for prevention and treatment of tuberculosis: a call for action Source: Eur Respir J, 50 (1) 1700946; 10.1183/13993003.00946-2017 Year: 2017 Resistance to second-line anti-tuberculosis drugs: new drug resistant TB treatment problem Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis Year: 2007 Potential antimicrobial agents for the treatment of multidrug-resistant tuberculosis Source: Eur Respir J 2014; 43: 884-897 Year: 2014 New drugs and drug regimens in the treatment of chronic and MDR-TB - what is on the horizon? Source: Annual Congress 2005 - Challenges in the management of pulmonary tuberculosis: a continuous clinical problem Year: 2005 Adverse effects of second-line drugs during the treatment of multidrug resistant tuberculosis patients Source: Eur Respir J 2005; 26: Suppl. 49, 650s Year: 2005 Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges Source: Eur Respir J 2016; 48: 938-943 Year: 2016